转移性透明细胞肾细胞癌患者中RECIST 1.1定义的影像学进展组成部分
该研究为III期METEOR试验的次要分析,纳入395例转移性透明细胞肾细胞癌患者,按RECIST 1.1判定进展事件。非靶病灶进展和新发病灶是最常见的进展原因,且这两类进展患者的中位无进展生存期短于靶病灶进展患者。
要点
- 非靶病灶进展占18.5%,新发病灶占26.6%,靶病灶进展占31.9%。
- 非靶病灶进展者中位PFS 2.8个月,新发病灶者3.6个月,均短于靶病灶进展者5.4个月(P < .01)。
- RECIST 1.1文献中认为不常见的非靶病灶和新发病灶进展,实际是影像学进展的最常见原因。
核心结论
- 肾细胞癌影像学进展最常见的原因是依据非靶病灶和新发病灶判定,而非靶病灶直径总和的变化,尽管后者在RECIST 1.1文献中被认为不常见。
研究设计与样本
- III期METEOR试验(2013年至2014年)的次要分析,纳入395例有至少一个基线靶病灶和一次随访时间点、按RECIST 1.1判定为进展的转移性透明细胞肾细胞癌患者,每个时间点采集胸部、腹部和盆腔扫描。
关键影像表现/征象
- 非靶病灶进展者73例(18.5%),新发病灶者105例(26.6%),靶病灶进展(定义为直径总和增加)者126例(31.9%)。
诊断标准与关键数值
- RECIST 1.1进展事件分类:非靶病灶进展、新发病灶、靶病灶进展(直径总和增加)。
- 非靶病灶进展者中位PFS 2.8个月(95%CI 1.9个月至3.7个月),新发病灶者3.6个月(95%CI 3.3个月至3.7个月),靶病灶进展者5.4个月(95%CI 5.0个月至5.5个月),组间差异P < .01。
临床应用与阅片要点
- 阅片和报告时应关注非靶病灶变化和新发病灶,二者是RECIST 1.1进展的常见组成部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Progression-free survival (PFS) determined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) is the reference standard to assess efficacy of treatments in patients with clear cell renal cell carcinoma. Purpose To assess the most common components of radiologic progressive disease as defined by RECIST 1.1 in patients with clear cell renal cell carcinoma and how the progression events impact PFS. Materials and Methods This secondary analysis of the phase III METEOR trial conducted between 2013 and 2014 included patients with metastatic clear cell renal cell carcinoma, with at least one target lesion at baseline and one follow-up time point, who were determined according to RECIST 1.1 to have progressive disease. A chest, abdominal, and pelvic scan were acquired at each time point. Kruskal-Wallis analysis was used to test differences in median PFS among the RECIST 1.1 progression events. The Holm-Bonferroni method was used to compare the median PFS of the progression events for the family-wise error rate of 5% to adjust P values for multiple comparisons. Results Of the 395 patients (296 men, 98 women, and one patient with sex not reported; mean age, 61 years ± 10), 73 (18.5%) had progression due to non-target disease, 105 (26.6%) had new lesions, and 126 (31.9%) had progression of target lesions (defined by an increase in the sum of diameters). Patients with progression of non-target disease and those with new lesions had shorter PFS than patients with progression defined by the target lesions (median PFS, 2.8 months [95% confidence interval {CI}: 1.9 months, 3.7 months] and 3.6 months [95% CI: 3.3 months, 3.7 months] vs 5.4 months [95% CI: 5.0 months, 5.5 months], respectively [P < .01]). Conclusion The most common causes for radiologic progression of renal cell carcinoma were based on non-target disease and new lesions rather than change in target lesions, despite this being considered uncommon in the Response Evaluation Criteria in Solid Tumors version 1.1 literature. © RSNA, 2019 See also the editorial by Kuhl in this issue.
引用
- Coy HJ, Douek ML, Ruchalski K, et al. Components of Radiologic Progressive Disease Defined by RECIST 1.1 in Patients with Metastatic Clear Cell Renal Cell Carcinoma. Radiology. 2019. PMID: 31084479. doi:10.1148/radiol.2019182922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。